CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials: JACC Review Topic of the Week Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation The mSToPS Randomized Clinical Trial The Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM) Coronary Calcium Atherosclerotic Cardiovascular Disease Risk Calculator Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: Findings from the American Heart Association’s COVID-19 Cardiovascular Disease Registry Influence of LDL-Cholesterol Lowering on Cardiovascular Outcomes in Patients With Diabetes Mellitus Undergoing Coronary Revascularization Predicting lifetime risk for developing atherosclerotic cardiovascular disease in Chinese population: the China-PAR project

ConsensusNovember 2018

JOURNAL:J Am Coll Cardiol. Article Link

2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways

Writing Committee, Sandeep RD, Brendan M et al. Keywords: ASCVD; cardiovascular risk reduction; diabetes; Expert Consensus; Decision Pathway; GLP-1RA; SGLT2 inhibitor; T2D

FULL TEXT PDF